Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients : Relationship with clinical and renal disease activity
Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease considered as an independent risk factor for mortality by cardiovascular disease. Currently, uric acid is described as a novel biomarker associated with cardiometabolic risk. However, nutritional and serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. This study aimed to assess the nutritional, biochemical, and cardiometabolic determinants of hyperuricemia and its relationship with clinical variables in SLE patients. A cross-sectional study was conducted in 167 SLE patients and 195 control subjects (CS). Nutrient intake, anthropometry, biochemical, and cardiometabolic indexes were evaluated. In SLE patients, adequate protein (OR = 0.4; p = 0.04) and carbohydrate (OR = 0.2; p = 0.01) intakes were associated with a lower risk of hyperuricemia. SLE patients with hyperuricemia presented a higher risk of clinical (OR = 2.2; p = 0.03) and renal activity (OR = 3.4; p < 0.01), as well as triglycerides ≥150 mg/dL (OR = 3.6; p < 0.01), hs-CRP ≥1 mg/L (OR = 3.1; p < 0.01), Kannel score ≥3 (OR = 2.5; p = 0.02), and BMI ≥25 kg/m2 (OR = 2.2; p = 0.02). Oppositely, serum levels of HDL-C ≥40 mg/dL (OR = 0.2; p < 0.01) were associated with a lower risk of hyperuricemia. According to the pharmacotherapy administered, prednisone treatment was associated with a high risk of hyperuricemia (OR = 4.7; p < 0.001). In contrast, the hydroxychloroquine treatment was associated with a lower risk of hyperuricemia (OR = 0.4; p = 0.02). In conclusion, SLE patients with hyperuricemia presented a high risk of clinical and renal activity as well as worse cardiometabolic status. Notably, an adequate intake of protein, carbohydrates, healthy HDL-C serum levels, and hydroxychloroquine treatment could be determinants of lower risk of hyperuricemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Lupus - 32(2023), 2 vom: 27. Feb., Seite 270-283 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Campos-López, Bertha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 22.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/09612033221146923 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350737312 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350737312 | ||
| 003 | DE-627 | ||
| 005 | 20231226045654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/09612033221146923 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350737312 | ||
| 035 | |a (NLM)36562214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Campos-López, Bertha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients |b Relationship with clinical and renal disease activity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 22.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease considered as an independent risk factor for mortality by cardiovascular disease. Currently, uric acid is described as a novel biomarker associated with cardiometabolic risk. However, nutritional and serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. This study aimed to assess the nutritional, biochemical, and cardiometabolic determinants of hyperuricemia and its relationship with clinical variables in SLE patients. A cross-sectional study was conducted in 167 SLE patients and 195 control subjects (CS). Nutrient intake, anthropometry, biochemical, and cardiometabolic indexes were evaluated. In SLE patients, adequate protein (OR = 0.4; p = 0.04) and carbohydrate (OR = 0.2; p = 0.01) intakes were associated with a lower risk of hyperuricemia. SLE patients with hyperuricemia presented a higher risk of clinical (OR = 2.2; p = 0.03) and renal activity (OR = 3.4; p < 0.01), as well as triglycerides ≥150 mg/dL (OR = 3.6; p < 0.01), hs-CRP ≥1 mg/L (OR = 3.1; p < 0.01), Kannel score ≥3 (OR = 2.5; p = 0.02), and BMI ≥25 kg/m2 (OR = 2.2; p = 0.02). Oppositely, serum levels of HDL-C ≥40 mg/dL (OR = 0.2; p < 0.01) were associated with a lower risk of hyperuricemia. According to the pharmacotherapy administered, prednisone treatment was associated with a high risk of hyperuricemia (OR = 4.7; p < 0.001). In contrast, the hydroxychloroquine treatment was associated with a lower risk of hyperuricemia (OR = 0.4; p = 0.02). In conclusion, SLE patients with hyperuricemia presented a high risk of clinical and renal activity as well as worse cardiometabolic status. Notably, an adequate intake of protein, carbohydrates, healthy HDL-C serum levels, and hydroxychloroquine treatment could be determinants of lower risk of hyperuricemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiometabolic risk | |
| 650 | 4 | |a clinical activity | |
| 650 | 4 | |a health determinants | |
| 650 | 4 | |a hyperuricemia | |
| 650 | 4 | |a uric acid | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Meza-Meza, Mónica R |e verfasserin |4 aut | |
| 700 | 1 | |a Pesqueda-Cendejas, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Ballesteros, Adolfo I |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera-Escoto, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas-Morales, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a Parra-Rojas, Isela |e verfasserin |4 aut | |
| 700 | 1 | |a Mora-García, Paulina E |e verfasserin |4 aut | |
| 700 | 1 | |a Vizmanos, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Montoya-Buelna, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Cerpa-Cruz, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a De la Cruz-Mosso, Ulises |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lupus |d 1991 |g 32(2023), 2 vom: 27. Feb., Seite 270-283 |w (DE-627)NLM012651214 |x 1477-0962 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:2 |g day:27 |g month:02 |g pages:270-283 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/09612033221146923 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 2 |b 27 |c 02 |h 270-283 | ||